European Pharmaceutical Review
OCTOBER 30, 2024
A paper has a described the first reported use of nanoemulsions as a novel delivery vehicle for the oral drug bedaquline (BDQ) “with high loading efficiency as a liquid dosage form”, according to the authors. The researchers explained that in recent decades, the industry has placed significant focus on lipid-based nanocarrier formulations for oral drug delivery.
Pharmafile
OCTOBER 30, 2024
Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise Sumagen’s human immunodeficiency virus (HIV) -1 vaccine candidate (SAV0001) at bench scale. First of its kind in human vaccine trials, SAV001 is a whole-killed and genetically modified HIV vaccine. During phase 1 of the clinical […] The post HIV vaccine candidate successfully optimised for industrial production appeared first on Pharmafile.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 30, 2024
All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
Fierce Pharma
OCTOBER 30, 2024
Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer’s general election. | As part of the new budget presented Wednesday by the U.K.’s Chancellor of the Exchequer, Rachel Reeves, the country is debuting a new capital grants vehicle known as the Life Sciences Innovative Manufacturing Fund.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
OCTOBER 30, 2024
LONDON — GSK’s once booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the company’s RSV vaccine, which became a blockbuster after debuting last year, fell by more than 70% year over year, in part due to narrower U.S. recommendations for who should get the shot.
Pharmafile
OCTOBER 30, 2024
Pharma Tech Industries, a pharmaceutical manufacturing and packaging solutions contractor for wellness products and medical devices, has announced the appointment of their new chief executive officer Darrin T Schellin. “I am honoured to join Pharma Tech Industries at such an exciting time in its journey,” said Mr Schellin. “As I step into this leadership role, […] The post Darrin Schellin appointed new CEO at Pharma Tech Industries appeared first on Pharmafile.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
OCTOBER 30, 2024
Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculat | Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of analyst expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation that skyrocketing demand for the blood sugar modulating treatments has maxed out.
STAT
OCTOBER 30, 2024
Health tech investments are showing signs of resilience following the perilous lows of 2022 and 2023: Just this past month, two startups that analysts believe might be getting ready for IPOs raised more than $100 million in late-stage funding rounds. And deal volume hit a record high in the second quarter, largely from early-stage deals, according to a Silicon Valley Bank analysis.
pharmaphorum
OCTOBER 30, 2024
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for drugs in its class.Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the period used to achieve therapeutic levels in the body – is enough to lower the incidence of a potentially serious side effect known as ARIA-E, accordi
Drug Topics
OCTOBER 30, 2024
Cassandra Esperant, PharmD, AAHIVP, leverages her skills as a clinical pharmacist to champion the health of patients with HIV, both in her clinical practice and through education initiatives.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmaVoice
OCTOBER 30, 2024
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
Drug Topics
OCTOBER 30, 2024
Explore what to look for in a solution to effectively manage cash pricing.
Pharmacy Times
OCTOBER 30, 2024
Results indicate that sublingual epinephrine can resolve symptoms, including swelling of the face and throat, associated with oral allergy syndrome in minutes.
Drug Topics
OCTOBER 30, 2024
Timothy Aungst, PharmD, Founder of The Digital Apothecary, discussed advancements in digital health and what to be aware of regarding the future of technology.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 30, 2024
This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.
Drug Topics
OCTOBER 30, 2024
Researchers addressed the gut-first hypothesis of Parkinson disease by identifying how mucosal damage impacts risk of development.
STAT
OCTOBER 30, 2024
The STAT Diversity and Inclusion Committee presents STAT’s 2024 Diversity and Inclusion Report. Here, we share the self-reported gender and racial/ethnic demographics of our staff from STAT’s inception in 2015 through 2023, as well as our 2023 new hire demographics. STAT’s Inaugural Diversity and Inclusion Report, published last year, is available here.
Drug Topics
OCTOBER 30, 2024
Women experiencing later menopause may face a heightened risk of asthma, underscoring the possible role of estrogen in the development of the condition.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
OCTOBER 30, 2024
Eli Lilly’s third-quarter sales and earnings were lower than expected, a rare stumble for the company that had consistently reported strong sales and beat earnings forecasts since demand for its blockbuster weight loss and diabetes drugs began booming. The company reported Wednesday overall revenue of $11.4 billion, lower than the $12.2 billion expected from analysts polled by Visible Alpha.
Pharmacy Times
OCTOBER 30, 2024
The risk of developing lymphoma remained nearly the same between patients with Crohn disease and ulcerative colitis.
STAT
OCTOBER 30, 2024
Axonis Therapeutics, a biotech company that has been quietly operating for the last five years, has raised $115 million after retooling its drug pipeline. The startup announced Wednesday that it closed a Series A round led by Cormorant Asset Management and venBio Partners — its first major financing after subsisting on a string of seed financing deals.
Fierce Healthcare
OCTOBER 30, 2024
At the HLTH 2024 conference in Las Vegas last week, attendees and exhibitors felt that the air had shifted around artificial intelligence. | The conversation around AI has shifted as health systems have begun to integrate operational solutions into their workflows.
Fierce Pharma
OCTOBER 30, 2024
Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.
Fierce Healthcare
OCTOBER 30, 2024
Humana updated its outlook for the year thanks to a Q3 where it beat the Street on both earnings and revenue. | Humana updated its outlook for the year thanks to a Q3 where it beat the Street on both earnings and revenue.
pharmaphorum
OCTOBER 30, 2024
Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales
PharmaVoice
OCTOBER 30, 2024
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
Fierce Pharma
OCTOBER 30, 2024
Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to distributors. | Baxter plans to exit China's IV fluids market as it faces tough local competition and as it redirects global IV supplies to the U.S. to cope with a post-hurricane shortage.
pharmaphorum
OCTOBER 30, 2024
Discover how GenAI is leveraging AI technology to streamline R&D processes, ensuring trusted data and accelerating drug discovery timelines while reducing costs.
Fierce Pharma
OCTOBER 30, 2024
It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug maker’s clutch of approved therapies under its fold. | In the third quarter, the company's overall sales grew 23% year over year and 8% excluding contributions from its Horizon Therapeutics buyout to $8.5 billion.
pharmaphorum
OCTOBER 30, 2024
The UK's first female Chancellor Rachel Reeves pumps billions into NHS in the first Labour budget in 14 years
STAT
OCTOBER 30, 2024
Semaglutide, better known as Ozempic and Wegovy, helped alleviate pain from knee osteoarthritis and improve function in patients with severe obesity, a new study found. The results of the 68-week trial were published in the New England Journal of Medicine , and could pave the way for a future FDA approval of GLP-1 receptor agonists for the joint-degrading condition.
pharmaphorum
OCTOBER 30, 2024
The head of AstraZeneca's Chinese operations, Leon Wang, has been placed under investigation by the authorities in Beijing
Fierce Healthcare
OCTOBER 30, 2024
Physicians and other healthcare practitioners may get a pay boost in 2025 through a bipartisan bill introduced in Congress on Tuesday. | The bill would increase the 2025 Physician Fee Schedule conversion factor by 4.73%, which would wipe out the expected 2.8% cut to the conversion factor and provide an approximately 1.9% inflationary payment increase for 2025.
Expert insights. Personalized for you.
Let's personalize your content